Since its inception, investor focus on AbbVie Inc. has centered on how it will foster commercial growth once top-seller Humira (adalimumab) faces biosimilar competition. Copies of the immunology blockbuster are now rolling out in Europe under settlements negotiated by AbbVie with various drug makers, two of which also set 2023 US launch dates for Humira biosimilars. (Also see "Sandoz And AbbVie Biosimilar Humira Settlement: What Does It Mean?" - Scrip, 12 October, 2018.)
Q3 Pharma Earnings Preview: AbbVie, Lilly, AstraZeneca And Bayer
AbbVie faces analysts just a couple weeks after Humira biosimilars hit the market, and with Gilead launching authorized generics of its hepatitis C combos, the TNF franchise is not the only one under attack at AbbVie. Investors are keen to see AstraZeneca start its turnaround to growth, while Lilly is looking to a strong future based on new diabetes data and Bayer braces for a new push in oncology.
